Kymera Therapeutics' GAAP loss for 3 months of 2022 was $36.684 million, up 2.8 times from $13.075 million in the previous year. Revenue decreased by 48.6% to $9.622 million compared to $18.702 million a year earlier.

Kymera Therapeutics' GAAP loss for 2021 was $100.217 million, up 2.2 times from $45.593 million in the previous year. Revenue increased 2.1 times to $72.832 million from $34.034 million a year earlier.

Kymera Therapeutics reported a GAAP loss of $66.317 million for 9M 2021, doubling from $32.908 million in the previous year. Revenue increased 2.7 times to $57.557 million from $21.249 million a year earlier.

Kymera Therapeutics' GAAP loss for six months of 2021 was $37.735 million, up 51.4% from $24.921 million in the prior year. Revenue increased 5.5 times to $37.221 million from $6.716 million a year earlier.